2Xideas AG Has $18.13 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

2Xideas AG increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 24.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 379,240 shares of the biopharmaceutical company's stock after purchasing an additional 73,653 shares during the period. Halozyme Therapeutics accounts for about 2.4% of 2Xideas AG's holdings, making the stock its 9th biggest holding. 2Xideas AG owned approximately 0.30% of Halozyme Therapeutics worth $18,131,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in HALO. Smartleaf Asset Management LLC raised its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the period. Louisiana State Employees Retirement System increased its stake in Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock worth $1,688,000 after buying an additional 200 shares during the period. State of New Jersey Common Pension Fund D lifted its holdings in Halozyme Therapeutics by 0.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock worth $2,279,000 after buying an additional 302 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares during the last quarter. Finally, Nations Financial Group Inc. IA ADV boosted its position in Halozyme Therapeutics by 2.4% in the 4th quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company's stock valued at $672,000 after buying an additional 328 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares of the company's stock, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,200 shares of company stock worth $1,286,568. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $2.32 during mid-day trading on Friday, reaching $60.02. The company's stock had a trading volume of 423,570 shares, compared to its average volume of 1,401,486. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $66.00. The business has a 50 day moving average price of $60.15 and a 200-day moving average price of $54.90. The firm has a market cap of $7.41 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

HALO has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Benchmark reaffirmed a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.